This library contains logic to expose configurable conversion factors for the MME calculation functionality provided by the OMTKLogic library.

Model definition for the FHIR R4 (v4.0.1) Model

This library contains logic to surface the MME calculation functionality provided by the OMTKLogic library by extracting appropriate information from FHIR R4 MedicationRequest resource.

This library contains drug ingredient data for opioid ingredients of combinations drugs as determined using the RxNav API. The content was produced using the process described here.

This library provides functionality for calculating Morphine Milligram Equivalents (MME) for opioid medications, as described in the CDC 2016 Opioid Prescribing Guideline.

Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.

Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.

Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.

When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.

When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.

When opioids are started, providers should prescribe the lowest effective dosage.

When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.

Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation. Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.

Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain.

When prescribing opioids for chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

When prescribing opioids for chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

When prescribing opioids for chronic pain, providers should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.

Concurrently prescribing opioid medications with benzodiazepines increases the risk of harm for the patient.

Arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder.